Chemistry:Bedinvetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Librela |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.[2][3][5] Librela is sponsored by Zoetis.[5][4]
The most common side effects include increased blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation (dermatitis), rash (erythema) or pain at injection site, vomiting (emesis), and weight loss (anorexia).[5]
Bedinvetmab was approved for medical use in the European Union in November 2020,[3] and in the United States in May 2023.[5][4] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.[5]
Medical uses
Bedinvetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.[5][3]
History
Two field studies were conducted to evaluate the effectiveness of bedinvetmab – one in the United States[6] and one in the European Union.[5] Both studies enrolled client-owned dogs diagnosed with osteoarthritis.[5] Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses.[5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered with the dog's daily activities.[5] The weight of evidence from the two field studies demonstrated that bedinvetmab is effective at controlling pain associated with osteoarthritis in dogs when at least two doses are given 28 days apart.[5]
Society and culture
Names
Bedinvetmab is the international nonproprietary name.[7] There is a Facebook group LIBRELA REVIEWS & FEEDBACK which has reports from pet owners and veterinarians regarding their experience with Librela. The group features both successes as well as those dogs who experienced severe side effects to include death.
References
- ↑ "Product information". https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100098.
- ↑ 2.0 2.1 https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13959
- ↑ 3.0 3.1 3.2 3.3 "Librela EPAR". 21 February 2022. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/librela.
- ↑ 4.0 4.1 4.2 "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.
- ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 "FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain". 5 May 2023. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-monoclonal-antibody-dogs-osteoarthritis-pain.
This article incorporates text from this source, which is in the public domain.
- ↑ Krautmann, M.; Walters, R.; Cole, P.; Tena, J.; Bergeron, L.M.; Messamore, J.; Mwangi, D.; Rai, S. et al. (October 2021). "Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs" (in en). The Veterinary Journal 276: 105733. doi:10.1016/j.tvjl.2021.105733. https://linkinghub.elsevier.com/retrieve/pii/S1090023321001283.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information 33 (3). 2019.
This article incorporates public domain material from the United States Department of Health and Human Services website https://www.fda.gov/.
Further reading
- "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis". Veterinary Anaesthesia and Analgesia 48 (6): 943–955. November 2021. doi:10.1016/j.vaa.2021.08.001. PMID 34565678.
- "Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs". Veterinary Journal 276: 105733. October 2021. doi:10.1016/j.tvjl.2021.105733. PMID 34391918.
 |  |
